[1]Velayudham LS,Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf,2003,2(3):287-304.[2]Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis,2013,17(2):191-209.[3]陈晓霞,杨海敏,姜娜. 110例药物性肝炎的病因和临床分析.实用医技杂志,2008,15(13):1728-1730.[4]Lazerow SK,Abdi MS,Lewis JH. Drug-induced liver disease 2004. Curr Opin Gastroenterol,2005,21(3):283-292.[5]Bleibel W,Kim S,D'Silva K,et al. Drug-induced liver injury: review article. Dig Dis Sci,2007,52(10):2463-2471. [6]彭东晖,汪锺贤.关于抗结核药物副作用的几个问题.临床荟萃,1986,1(11):21-25.[7]肖成志. 第一线抗结核药物的副作用.中华结核和呼吸杂志,1979,2(3):227.[8]郭英江,崔德键. 抗结核药所致肝损害.中华结核和呼吸杂志,1998,21(5):308-309.[9]夏愔愔,詹思延. 国内抗结核药物不良反应发生率的综合分析.中华结核和呼吸杂志,2007, 30(6):419-423.[10]Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol,2008,23(2): 192-202.[11]雷建平,予季. 呼吸系统救护治疗学.南昌:江西科学技术出版社,2008.[12]Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle,1978,59(1):13-32.[13]刘向宏,王一丁,潘丽芳,等. 喹诺酮类药物研究进展及毒性分析.辽宁化工,2010,39(4): 431-434.[14]吴敏,吴洪文,李锦燊.氨基糖苷类药物的不良反应及防治对策.抗感染药学,2008,5(4):252-254.[15]程辉跃. HPLC法测定帕司烟肼片中对氨基水杨酸和异烟肼的含量.药物分析杂志,2000, 20(3): 186-188.[16]Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors,prevention and managerment. Indian J Exp Biol,2003,41(11):1226-1232. [17]Deng R, Yang T, Wang Y, et al. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis,2012,16(12):1574-1581. [18]Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis,2008,12(9):994-1002. [19]Hercus CG, Khoo JK, Jones TE. A case of hyperacute hepatotoxicity in response to tuberculosis therapy. Int J Tuberc Lung Dis,2012,16(12):1709-1710.[20]Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One,2011,6(12):e27810. [21]Cai Y, Yi J, Zhou C, et al. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One,2012,7(10): e47769.[22]Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol,2008,23(2):192-202.[23]Hoffmann CJ, Charalambous S, Thio CL,et al.Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS,2007,21(10):1301-1308.[24]Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis,2005,5:58.[25]Lima Mde F, Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica,2012,28(4):698-708.[26]Grupo Colaborativo En Hepatitis B. Clinical practice guideline for diagnosis and treatment of chronic hepatitis virus hepatitis B. Grupo Colaborativo en Hepatitis B[Article in Spanish]. Rev Gastroenterol Peru,2011,31(2):151-168. [27]中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 中华传染病杂志,2011,29(2):65-80.[28]EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL clinical practice guidelines: Management of hepatitis C virus infection.J Hepatol,2011,55(2):245-264.[29]中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华医学杂志,2004,84(9):775-780.[30]游宏声,金生. 2011年欧洲肝病研究学会丙型肝炎防治指南推荐意见介绍.实用肝脏病杂志, 2011,14(4):307-308,320.[31]European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol,2012,57(2):399-420. [32]Barve A, Khan R, Marsano L, et al.Treatment of alcoholic liver disease.Ann Hepatol,2008,7(1): 5-15.[33]中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南(2010年1月修订).胃肠病学,2010, 15 (10):617-621.[34]Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Am J Gastroenterol,2012,107(6):811-826.[35]Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.Dig Liver Dis,2010,42(4):272-282.[36]中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊疗指南(2010年修订版).胃肠病学和肝病学杂志,2010,19(6):483-487.[37]Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut,2011,60(12): 1611-1629. [38]张玉波,段维佳,贾继东. 2010 年美国肝病学会自身免疫性肝炎诊治指南要点.肝脏,2010, 15(5):367-371.[39]雷建平. 重新审视结核病免疫治疗研究的方向和方法. 中华临床医师杂志(电子版),2010,4(7):908-915.[40]宿砚明,张宗明. 肝内胆汁淤积症的诊断和治疗.世界华人消化杂志,2008,16(11):1210-1214.[41]Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol,1990,28(8):317-322. [42]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版).中华肝脏病杂志, 2012,21 (3):177-183.[43]Lv G, Zhao L, Zhang A, et al. Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs. Biotechnol Bioeng,2011,108(9):2229-2236. [44]Lee JH, Lee DH, Park JK, et al. Effect of fulminant hepatic failure porcine plasma supplemented with essential components on encapsulated rat hepatocyte spheroids. Transplant Proc,2012,44(4): 1009-1011. |